GlassScriptPhysician profile
Michael Steven Rogers
NPI 1184684268
$6,348.72
in general payments reported to CMS, 2019-2025
48 companies · $1,143 in 2025
The $1,143 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $753 · 2021: $748 · 2022: $1,100 · 2023: $1,087 · 2024: $1,042 · 2025: $1,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,272.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,043.70 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $810.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $630.90 | 2019-2025 | |
| Glaxosmithkline, LLC. | $522.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $335.42 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Nuvasive, INC. | $326.20 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $302.90 | 2020-2024 | Xifaxan |
| Abbott Laboratories | $263.36 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $253.17 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $224.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $113.12 | 2020 | |
| Vanda Pharmaceuticals INC. | $111.45 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $105.25 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Amgen INC. | $101.02 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.07 | 2019-2025 | Jardiance |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.